Yale School of Public Health outlining COVID-19 is not mild

Five years with SARS-CoV-2 in our midst, and the CDC reports that 43 million Americans have experienced Long COVID. Some have recovered, but roughly 17 million - the same number of people who have cancer in the U.S. - still deal with the condition, and that number continues to grow. At Yale, Dr. Akiko Iwasaki's laboratory is investigating how the virus can create long-lasting impacts on the immune system. And with many left incapacitated by the novel condition and at risk from rolled-back mitigations, the desperate need for answers grows. "There is a lot we don't know," Dr. Iwasaki says. "Based on our insights of the drivers of Long COVID disease, we need to develop diagnostics and therapies that restore healthy immune systems and [people's] health back to normal." As the CDC states, Long COVID can happen to anyone. But thanks to the dedicated work of scientists like Dr. Iwasaki across the world, there are a few knowns. Scroll through for the explanations we have, and the ones 17 million Americans, and counting, need. Correction: We've updated slide 6 to read 72%, not 172%, though other studies have found the risk of autoimmune disorders increased by 198% following infection.

This was published on Yale's Public Health's Facebook page  on April 19, 2024. Secondarily published to pdflink.to - uploaded by principal author.  Here below too as a slide carousel:

COVID-19 and Immune System Impacts, Source Citations 

Slide 2: 

Slide 3: 

Slide 4: 

Slide 5: 

Slide 6: 

Slide 7: 

Slide 8: 

Slide 9: